A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects

Trial Profile

A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs LY 3305677 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jun 2017 Planned End Date changed from 14 Jun 2017 to 14 Jul 2017.
    • 19 Jun 2017 Planned primary completion date changed from 14 Jun 2017 to 14 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top